Study design, setting, and ethical approval

TW Takeshi Wada
AS Atsushi Shiraishi
SG Satoshi Gando
KY Kazuma Yamakawa
SF Seitaro Fujishima
DS Daizoh Saitoh
SK Shigeki Kushimoto
HO Hiroshi Ogura
TA Toshikazu Abe
TM Toshihiko Mayumi
JS Junichi Sasaki
JK Joji Kotani
NT Naoshi Takeyama
RT Ryosuke Tsuruta
KT Kiyotsugu Takuma
NY Norio Yamashita
SS Shin-ichiro Shiraishi
HI Hiroto Ikeda
YS Yasukazu Shiino
TT Takehiko Tarui
TN Taka-aki Nakada
TH Toru Hifumi
KO Kohji Okamoto
YS Yuichiro Sakamoto
AH Akiyoshi Hagiwara
TM Tomohiko Masuno
MU Masashi Ueyama
SF Satoshi Fujimi
YU Yutaka Umemura
YO Yasuhiro Otomo
request Request a Protocol
ask Ask a question
Favorite

This is a prognostic study performed as a sub-analysis of a multicenter prospective descriptive cross-sectional study conducted by the Japanese Association for Acute Medicine (JAAM) Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis and Trauma (FORECAST) study group15. The JAAM FORECAST TRAUMA study recruited participants from April 1, 2016, to January 31, 2018, from 39 emergency departments and intensive-care units (ICUs) in tertiary hospitals and was registered at the University Hospital Medical Information Network Clinical Trial Registry. (UMIN-CTR ID: UMIN000019588). This study was approved under the condition that written informed consent should be obtained from either the patient or their next of kin by the JAAM and the Ethics Committee of each hospital (JAAM, 2014-01; Hokkaido University Graduate School of Medicine, Head institute of the FORECAST group, 014-0307) and was performed in accordance with Declaration of Helsinki.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A